<DOC>
	<DOC>NCT00294723</DOC>
	<brief_summary>This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).</brief_summary>
	<brief_title>To Evaluate the Effect of Liraglutide Versus Glimepiride (AmarylÂ®) on Haemoglobin A1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes TTreatment with diet/exercise or with not more than half maximal dose of oral antidiabetic drugs alone for at least 2 months Diet/exercise treated subjects with HbA1c between 7.0% and 11%, inclusive OAD (oral antidiabetic drug) treated subjects with HbA1c between 7.0% and 10%, inclusive Body Mass Index (BMI) less than or equal to 45 kg/m^2 Treatment with insulin for the last 3 months, except shortterm treatment for intercurrent illness Treatment with any drug that could interfere with the glucose level (besides use of a single antidiabetic compound) Any serious medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>